TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06286436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: The intervention will consist of three different tasks that participants have to carry out while performing mental calculations (counting backwards from 100 by ones, twos, and threes). The three tasks will be as follows: grouping blocks of different colours into groups according to colour; picking up beans with a spoon and carrying them to a specific place; opening and closing a bottle cap with the affected hand. The total duration of the intervention will be 12 sessions, divided into three days per week for four weeks.
Study: NCT05850520

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein
Description: Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
Study: NCT06084936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive IV glofitamab beginning Cycle 1 Day 8 for 12 cycles (cycle length = 21 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Participants will receive IV rituximab every 28 days for up to 6 cycles (when in combination with bendamustine), or until disease progression (when in combination with lenalidomide).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Participants will receive IV bendamustine on Days 1 and 2 Q4W for 6 cycles (cycle length = 28 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Participants will receive oral lenalidomide once daily on Days 1-21 Q4W until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as required to manage cytokine release syndrome (CRS) events.
Study: NCT05810285

Intervention type: DEVICE
Intervention: GKS Prime Flex Mobile knee
Description: Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis

Intervention type: DEVICE
Intervention: GKS Prime Flex Mobile knee
Description: Total knee arthroplasty with a cemented mobile bearing bicompartmental knee prosthesis
Study: NCT05227586

Intervention type: PROCEDURE
Intervention: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.

Intervention type: PROCEDURE
Intervention: Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablation
Description: Patients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.
Study: NCT05132725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet therapy
Description: Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet therapy
Description: Adjusting the quantity and quality of food intake to improve glycemic control, growth rate and quality of life among children with type 1 diabetes and celiac disease.
Study: NCT05755087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegavivint
Description: Given IV
Study: NCT06061406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart visit app
Description: Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart visit app
Description: Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smart visit app
Description: Patients use an obesity-adapted version of aycan's Smartvisit app, which helps track specific behaviors (diet, exercise), query potential problems/complaints, and manage medical documents in a structured way.~A study nurse experienced in the field of nutrition/obesity contacts the patient if necessary and establishes contact with the center physician.
Study: NCT05630625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking Dashboard
Description: Day-level feedback on alcohol use and consequences
Study: NCT06063655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV sugar-free hydration multiplier
Description: Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
Study: NCT05440019

Intervention type: DEVICE
Intervention: IMAGE CAPTURE SESSION
Description: The M3T FERTIGO® is an instrument to be used by a certified gynecologist and in particular by an IVF expert physician in order to observe and monitor the state of the endometrium lining of patients. The M3T device serves as a mini hysteroscope capable of magnification, capturing images and optional image processing thereof. The M3T enables to acquire in-vivo, magnified images of the endometrium surface, to identify key morphological parameters, calculate their attributes and statistics thereof and compare those for different acquisition images and to some standard tissue state tracks. One may then attempt to predict the Embryo transfer optimal timing, based on this analysis.
Study: NCT05815082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colorectal cancer resection combined with liver metastasis resection.
Description: The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.
Study: NCT06063655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV sugar-free hydration multiplier
Description: Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV sugar-free hydration multiplier
Description: Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV sugar-free hydration multiplier
Description: Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid IV sugar-free hydration multiplier
Description: Liquid IV sugar-free hydration multiplier will be provided to subject divided into 3 equal portions with each portion consumed over 10 minutes with 15 minutes between portions (rehydration period of 1 hour).
Study: NCT05815082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal cancer resection combined with liver metastasis resection.
Description: The preferred surgical approach is resection of the corresponding colon segment with regional lymph node dissection. If conditions permit, synchronous resection of the primary lesion and liver metastases of colorectal cancer can be performed to achieve curative resection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX chemotherapy regimen
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Study: NCT05900752

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: QiMeiYan Probiotics
Description: consume one sachet of the assigned product, once a day after meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: consume one sachet of the assigned product, once a day after meals.
Study: NCT06410963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactivate
Description: The study period is 84 days (12 weeks). Depending on the length of the baseline period (randomly assigned to be 7, 14 or 21 days), the treatment period varies between 63-77 days and contains 6-11 sessions. The intervention consists of 2-4 educational sessions in pain mechanisms and fear avoidance and 4-9 sessions of individually tailored intervention with graded exposure and reactivation to avoided physical activities. Intervention will take place from one time per week to one time every two weeks, 30-60 minutes per session. Number of treatment sessions will depend on when the individual participants' goals are considered reached. If necessary, given the participants consent, their legal guardians will be invited to attend the sessions.
Study: NCT05056753

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HWBV chair
Description: vibration-actuated, saddle-seat type stool

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HWBV chair
Description: vibration-actuated, saddle-seat type stool
Study: NCT06462963

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: single-fraction SBRT
Description: Single-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers a high dose of radiation in a single treatment session to a targeted area, often used for treating small, well-defined tumors. This approach minimizes exposure to surrounding healthy tissues while effectively treating the tumor.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: multiple-fraction SBRT
Description: Multiple-fraction SBRT (Stereotactic Body Radiation Therapy) is a precise form of radiation therapy that delivers high doses of radiation over several treatment sessions to a targeted area, typically used for treating small, well-defined tumors. This method helps to further protect surrounding healthy tissues by spreading the total radiation dose over multiple sessions.
Study: NCT05539248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN106 20 mg/kg
Description: Induction and maintenance dosing for cohort 1:~12 mg/kg on Day 1, 16 mg/kg on Day 8, and 20 mg/kg on Day 15 and every 4 weeks thereafter;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN106 40 mg/kg
Description: Induction and maintenance dosing for cohort 2:~30 mg/kg on Day 1, and 40mg/kg on Day 8 and every 4 weeks thereafter；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN106 80 mg/kg
Description: Induction and maintenance dosing for cohort 3:~60 mg/kg on day 1, and 80 mg/kg on day 15 and every 8 weeks thereafter.
Study: NCT06249204

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching Group
Description: Over a six-month coaching program period, staff members from care communities work with a coach to assess their current level of adoption of Dementia Care Practice Recommendations (DCPR) (published recommendations by Alzheimer's Association) and prioritize areas of need /focus. Teams meet with the coach virtually or in person for 1 hour each month during the six months. Through an action planning and implementation process, care communities are guided to make organization-wide, measurable changes in the areas of (1) policies and procedures, (2) education and training, and/or (3) care practices to increase and maintain person-centered care practices as outlined in the DCPR. Coaches provide ongoing support to the care community through telephone and email support between meetings.
Study: NCT05274334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of de novo lipogenesis non-invasively in exhaled breath
Description: 1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements.~2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish.~3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water.~4. Participants execute several exhalation sets over time.~5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert.~6. Participants execute several exhalation sets over time.~7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded.
Study: NCT04956146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib，Sintilimab，Pemetrexed，Carboplatin
Description: Fruquintinib,fruquintinib at the dose determined in phase safety lead-in,5mg-intermittent (2 weeks on/ 1 week off) ，po，every 3 weeks(q3w) ; Sintilimab at the dose 200mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=4\~5，iv，d1；given every 3 weeks (q3w); Maintenance treatment：After 4\~6 cycles of carboplatin treatment, Sintilimab 200mg, iv, d1, q3w；Fruquintinib RP2D intermittent(2 weeks on/1 weeks off), po，q3w； pemetrexed 500mg/m2, d1,iv, q3w until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
Study: NCT05560815

Intervention type: PROCEDURE
Intervention: Any surgical procedure
Description: Might differ for substudies.
Study: NCT05331950

Intervention type: OTHER
Intervention: Office Workers
Description: Office Workers which will be observed/exposed with different task and different factors
Study: NCT06281886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Immunotherapy-Toripalimab
Description: Toripalimab 240mg iv. drip, Q3W, 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Immunotherapy-Toripalimab
Description: Toripalimab 240mg iv. drip, Q3W, 2 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin
Description: Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin
Description: Albumin-paclitaxel 260 mg/m2, administered on day 1, combined with cisplatin 25 mg/m2, administered on day 1,2,3.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Thoracic radiotherapy at a total dose of 50Gy was delivered using the intensity modulated radiation therapy technique.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Thoracic radiotherapy at a total dose of 50Gy was delivered using the intensity modulated radiation therapy technique.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Oral apatinib 250mg once daily during induction therapy and concurrent chemoradiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine 1000 mg/m2, twice daily, on days 1-14, every 3 weeks, concurrently with radiotherapy
Study: NCT05886634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Will be administered PO daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Will be administered IV every 2 weeks for 24 weeks
Study: NCT05665621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eight-week in-school strength and balance training program
Description: Training program consisting of two 1-hour strength and balance training sessions per week.
Study: NCT04863014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evinacumab
Description: Intravenous infusion every 4 weeks (Q4W)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion Q4W
Study: NCT05449613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acupoint application
Description: During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During the trial, if patients can not tolerate the pain, meloxicam tablets can be added temporarily, and the total amount of medication for each patient during the observation period was recorded.
Study: NCT04868591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single session of education and exercise provided by an advanced practice physiotherapist.
Description: In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participant will not receive additional care by the APPT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple session of education and exercise provided by an advanced practice physiotherapist.
Description: In a one-hour consultation, the APPT will assess and triage surgical candidates, recommend medical care (medication or injection), as well as provide education and prescribe a self-management exercise program aimed at impairments and functional limitations identified during the initial assessment. Participants will receive five additional consultations with the APPT within a 12-week period. During the follow-up visits, the APPT will reassess the participants, provide further education and recommendations, review and modify the home exercise program and may provide other rehabilitation interventions.
Study: NCT05890118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: A commercial formulation of ustekinumab for SC control (0.5mg)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-111 (0.5mg)
Description: RaniPill capsule containing ustekinumab with a dose of 0.5mg

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RT-111 (0.75mg)
Description: RaniPill capsule containing ustekinumab with a dose of 0.75mg
Study: NCT04982510

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: complete denture
Description: 3D printed complete denture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: complete denture
Description: 3D printed complete denture
Study: NCT04914832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: AZD1222 is a recombinant replication-defective chimpanzee adenovirus vaccine expressing the SARS-CoV-2 S surface glycoprotein.
Study: NCT05345886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: Hippotherapy is a rehabilitation method entrusted to a paramedic or medical practitioner who uses the horse in his/her program treatment, in addition to conventional medical care.
Study: NCT06012045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Cue Exposure Therapy
Description: The E-CET will consist of six weekly sessions and will be delivered by a clinical psychology trainee in person. The first session will be used to introduce the rationale and procedures of E-CET to the participant to establish therapeutic alliance, agreement on treatment goals and tasks, and to collect information on idiosyncratic CS-US expectancies to be targeted in exposures. In this session, questions will be asked specifically to assess idiosyncratic CS-US expectancies related to the four categories: positive reinforcement, craving/drive reduction, mood regulation, and disinhibition. An exhaustive list of all idiosyncratic NEE-triggering cues and CSUS expectancies will be generated from this session. These cues and CS-US expectancies will be targeted in the following exposure sessions and in homework exposures with the goal to cover as many of them as possible during the 6-week treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Lifestyle Intervention
Description: It consists of six weekly sessions of behavioral counseling integrating behavioral strategies for making changes related to diet and exercise. These behavioral strategies will include education about healthy and balanced diets, and ways to attain the minimum level of physical activity for wellbeing (150 minutes moderate-to-vigorous exercise per week), goalsetting, problem-solving, coping, and relaxation. A manualized protocol developed by the PI's team for previous studies in the local community will be used.